1. ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34 (38):2949-3003. D0I:10.1093/eurheartj/eht296
2. Бритов А. Н., Поздняков Ю. М., Волкова Э. Г., Драпкина О.М., Еганян Р. А., Кисляк О. М. и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011; 10 (6 S2):2-64. [Britov A. N., Pozdnyakov Yu. M., Volkova E. G., Drapkina O. M., Eganyan R. A. National recommendations of cardiovascular prevention. Cardiovascular therapy and prevention. 2001;10 (6 S2):2-64.]
3. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP etal. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/ST S Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60 (24):e44-164. D0I:10.1016/j. j acc.2012.07.013
4. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А.и др. Хроническая СН (ХСН). Журнал Сердечная Недостаточность. 2017; 18 (1):3-40. [Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. et al. Clinical guidelines. Chronic heart failure (CHF). Russian heart failure journal. 2017;18 (1):3-40.] D0I:10.18087/rhfj. 2017.1.2346
5. Аспирин кардио - официальная инструкция по применению, аналоги [Internet]. medi.ru. [cited 2018].
6. Hart RG, Leonard AD, Talbert RL, Pearce LA, Cornell E, Bovill E et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy. 2003;23 (5):579-84. PMID: 12741431
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71-86. PMID: 11786451
8. Cooke AR, Hunt JN. Absorption of acetylsalicylic acid from unbuffered and buffered gastric contents. Am J Dig Dis. 1970;15 (2):95-102. PMID: 4905590
9. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95 (10):1218-22. D0I:10.1016/j. amjcard. 2005.01.049
10. Fisher M, Knappertz V. Comments in response to 'Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials." Am J Cardiol. 2005;96 (10):1467. D0I:10.1016/j. amjcard. 2005.06.013
11. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26 (12):3264-72. PMID: 14633812
12. Багликов А. Н., Рафальский В. В. Значение приверженности пациентов к лечению при длительном приеме ацетилсалициловой кислоты у пациентов, перенесших ОКС: результаты исследования. Кардиология. 2012;52 (9):22-8. [A. N. Baglikov, V. V. Rafalsky. The Value of Compliance During Chronic Administration of Acetylsalicylic Acid in Patients With Acute Coronary Syndrome: Results of The Study "F0RP0ST"]
13. Schrr K. Acetylsalicylic Acid [Internet]. -Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2008Nov12 [cited 2018].
14. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117 (1):17-25. PMID: 10381905
15. Levy G. Levy G, Hayes B, "Physiochemical basis of the buffered acetylsalicylic acid controversy. New Engl.J. Med. 262:10531058 (1960)" - the backstory. AAPS J. 2011;13 (3):320-2. D01:10.1208/s12248-011-9280-y
16. Darius H. Pharmazeutische Zeitung online: Aspirin protect: Anwendungsbeobachtung dokumentiert gute Verträglichkeit [Internet]. 2006 [cited 2018].
17. Рафальский В. В., Крикова А. В., Багликов А. Н. Особенности клинической фармакологии ацетилсалициловой кислоты как антитромботического препарата. Кардиоваскулярная терапия и профилактика. 2009;8 (7):102-7. [Rafalskiy V. V., Krikova A. V., Baglikov A. N. Features of the clinical pharmacology of aspirin as antithrombotic drug. Cardiovascular therapy and prevention. 2009;8 (7):102-7.]
18. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 1999;13 (8):1109-14. PMID: 10468689
19. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130 (25):e344-426.D0I:10.1161 /CIR. 0000000000000134
20. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. ACC / AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110 (9):e82-292. PMID: 15339869
21. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32 (23):2999-3054. D0I:10.1093/eurheartj/ehr236
22. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33 (20):2569-619. D0I:10.1093/eurheartj/ehs215
23. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37 (38):2893-962. D0I:10.1093/eurheartj/ehw210
24. Li L, Geraghty 0C, Mehta Z, Rothwell PM, 0xford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390 (10093):490-9. D0I:10.1016/S0140-6736 (17) 30770-5
25. Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease - Full Text View - ClinicalTrials. gov [Internet]. [cited 2018].
26. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348 (9038):1329-39. PMID: 8918275
27. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354 (16):1706-17. D0I:10.1056/NEJMoa060989
28. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49 (19):1982-8. D0I:10.1016/j. jacc. 2007.03.025
Послать статью по эл. почте 
Оставить комментарий 
